{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:09:28Z","timestamp":1780592968367,"version":"3.54.1"},"reference-count":158,"publisher":"Elsevier","isbn-type":[{"value":"9780443432361","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acr.2026.02.003","type":"book-chapter","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:47:46Z","timestamp":1773146866000},"page":"143-185","source":"Crossref","is-referenced-by-count":0,"title":["Non-replicating adenoviral vectors for cancer gene therapy"],"prefix":"10.1016","author":[{"given":"Ana Laura Vieira","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Naomi","family":"Niitsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Carlos","family":"dos Santos da Luz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio Augusto","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia Barbosa","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan E.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/bs.acr.2026.02.003_bib0001","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/mt.2010.131","article-title":"Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model","volume":"18","author":"Ahmed","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/bs.acr.2026.02.003_bib0002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fimmu.2011.00040","article-title":"Immune recognition of gene transfer vectors: Focus on adenovirus as a paradigm","volume":"2","author":"Aldhamen","year":"2011","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0003","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/cancers10060178","article-title":"p53 and the viral connection: Back into the future (double dagger)","volume":"10","author":"Aloni-Grinstein","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0004","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.003_bib0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF03402119","article-title":"Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro","volume":"5","author":"Aoki","year":"1999","journal-title":"Mol Med"},{"issue":"3 Suppl 1","key":"10.1016\/bs.acr.2026.02.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2022-0079","article-title":"The use of adenoviral vectors in gene therapy and vaccine approaches","volume":"45","author":"Araujo","year":"2022","journal-title":"Genet Mol Biol"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.003_bib0007","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: Implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/bs.acr.2026.02.003_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coviro.2016.08.017","article-title":"Adenovirus sensing by the immune system","volume":"21","author":"Atasheva","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"1\u20133","key":"10.1016\/bs.acr.2026.02.003_bib0009","first-page":"1","article-title":"Targeted adenoviral vectors","volume":"1575","author":"Barnett","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1873-3468.13731","article-title":"Retargeting adenoviruses for therapeutic applications and vaccines","volume":"594","author":"Barry","year":"2020","journal-title":"FEBS Lett"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0011","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/v15051086","article-title":"Engineering adenoviral vectors with improved GBM selectivity","volume":"15","author":"Bates","year":"2023","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.003_bib0012","article-title":"Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma","volume":"33","author":"Biegert","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.003_bib0014","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nbt.2680","article-title":"Commensal cocktail suppresses gut inflammation","volume":"31","author":"Borowski","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/neuonc\/noz231","article-title":"Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: Results of a phase I\/II study","volume":"22","author":"Brenner","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/bs.acr.2026.02.003_bib0016","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.omtm.2021.01.002","article-title":"iMATCH: An integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy","volume":"20","author":"Brucher","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0022-2836(85)90186-X","article-title":"The structure of the adenovirus capsid. I. An envelope model of hexon at 6 A resolution","volume":"185","author":"Burnett","year":"1985","journal-title":"J Mol Biol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0020","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus-T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.003_bib0019","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: From molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0022","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1442-2042.2002.00464.x","article-title":"Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model","volume":"9","author":"Cheon","year":"2002","journal-title":"Int J Urol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0021","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1464-410x.2000.00516.x","article-title":"Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: Changes in tumour cell proliferative activity","volume":"85","author":"Cheon","year":"2000","journal-title":"BJU Int"},{"issue":"505","key":"10.1016\/bs.acr.2026.02.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci Transl Med"},{"issue":"25","key":"10.1016\/bs.acr.2026.02.003_bib0024","doi-asserted-by":"crossref","first-page":"38210","DOI":"10.18632\/oncotarget.9427","article-title":"Efficacy of CD46-targeting chimeric Ad5\/35 adenoviral gene therapy for colorectal cancers","volume":"7","author":"Cho","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41579-018-0003-6","article-title":"Autophagy during viral infection - a double-edged sword","volume":"16","author":"Choi","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0026","article-title":"VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: A single center, single arm, phase II trial","volume":"12","author":"Coffman-D\u2019Annibale","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.acr.2026.02.003_bib0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: The dark side of tumor suppression","volume":"5","author":"Coppe","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/bs.acr.2026.02.003_bib0028","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.003_bib0029","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4049\/jimmunol.1800219","article-title":"A prime-pull-amplify vaccination strategy to maximize induction of circulating and genital-resident intraepithelial CD8(+) memory T cells","volume":"202","author":"Cuburu","year":"2019","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.003_bib0030","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/1078-0432.CCR-23-3940","article-title":"Phase I trial of viral vector-based personalized vaccination elicits robust neoantigen-specific antitumor T-cell responses","volume":"30","author":"D\u2019Alise","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/bs.acr.2026.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","article-title":"Production of first generation adenovirus vectors: A review","volume":"7","author":"Danthinne","year":"2000","journal-title":"Gene Ther"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0032","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.ymthe.2022.08.002","article-title":"Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2","volume":"30","author":"Dicks","year":"2022","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.003_bib0033","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3390\/ijms19092694","article-title":"Targeting CD46 enhances anti-tumoral activity of adenovirus type 5 for bladder cancer","volume":"19","author":"Do","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0034","article-title":"Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade","volume":"33","author":"Domingues","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.003_bib0035","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1089\/hum.2017.140","article-title":"Recent advances in preclinical developments using adenovirus hybrid vectors","volume":"28","author":"Ehrke-Schulz","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.003_bib0036","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.tim.2007.09.003","article-title":"The benefits of using diverse animal models for studying pertussis","volume":"15","author":"Elahi","year":"2007","journal-title":"Trends Microbiol"},{"key":"10.1016\/bs.acr.2026.02.003_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571212","article-title":"Regulation of immunogenic cell death and potential applications in cancer therapy","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/bs.acr.2026.02.003_bib0038","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1111\/febs.16051","article-title":"Regulation of innate immune responses by cell death-associated caspases during virus infection","volume":"289","author":"Fang","year":"2022","journal-title":"FEBS J"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.003_bib0039","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41418-018-0212-6","article-title":"Pyroptosis versus necroptosis: Similarities, differences, and crosstalk","volume":"26","author":"Frank","year":"2019","journal-title":"Cell Death Differ"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.003_bib0041","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0042","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1038\/s41467-019-13744-8","article-title":"Artificially cloaked viral nanovaccine for cancer immunotherapy","volume":"10","author":"Fusciello","year":"2019","journal-title":"Nature communications"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.003_bib0043","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"issue":"1\u20132","key":"10.1016\/bs.acr.2026.02.003_bib0044","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jviromet.2013.04.013","article-title":"A rapid Q-PCR titration protocol for adenovirus and helper-dependent adenovirus vectors that produces biologically relevant results","volume":"192","author":"Gallaher","year":"2013","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: Concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.003_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101448","article-title":"In vivo HSC transduction in humanized mice mediated by novel capsid-modified HDAd vectors","volume":"33","author":"Georgakopoulou","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.003_bib0047","doi-asserted-by":"crossref","first-page":"e3721","DOI":"10.1002\/jgm.3721","article-title":"Gene therapy clinical trials worldwide to 2023-an update","volume":"26","author":"Ginn","year":"2024","journal-title":"J Gene Med"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0048","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0042-6822(67)90241-3","article-title":"Biochemical studies on adenovirus multiplication. XII. Plaquing efficiencies of purified human adenoviruses","volume":"31","author":"Green","year":"1967","journal-title":"Virology"},{"issue":"1\u20133","key":"10.1016\/bs.acr.2026.02.003_bib0049","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1021106116887","article-title":"Rapid titration of adenoviral infectivity by flow cytometry in batch culture of infected HEK293 cells","volume":"38","author":"Gueret","year":"2002","journal-title":"Cytotechnology"},{"key":"10.1016\/bs.acr.2026.02.003_bib0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","article-title":"Noncytolytic control of viral infections by the innate and adaptive immune response","volume":"19","author":"Guidotti","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295323","article-title":"Recombinant human adenovirus p53 combined with transcatheter arterial chemoembolization for liver cancer: A meta-analysis","volume":"18","author":"Guo","year":"2023","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0052","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ymthe.2025.03.062","article-title":"Four decades of adenovirus gene transfer vectors: History and current use","volume":"33","author":"Hackett","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/bs.acr.2026.02.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172991","article-title":"Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses","volume":"874","author":"Hadrys","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0054","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.cdd.4401833","article-title":"Viruses, endoplasmic reticulum stress, and interferon responses","volume":"13","author":"He","year":"2006","journal-title":"Cell Death Differ"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0055","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2025.2475831","article-title":"The seroprevalence of adenoviruses since 2000(1)","volume":"14","author":"Hong","year":"2025","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101537","article-title":"EF1alpha, rather than CMV promoter, is suitable for luciferase tag expression in target cells for in vitro cytotoxicity assays of CAR-T cells","volume":"33","author":"Hou","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"37","key":"10.1016\/bs.acr.2026.02.003_bib0058","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/onc.2012.458","article-title":"Mesenchymal stem cells promote growth and angiogenesis of tumors in mice","volume":"32","author":"Huang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/bs.acr.2026.02.003_bib0059","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.17","article-title":"Reestablishment of p53\/Arf and interferon-beta pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death","volume":"3","author":"Hunger","year":"2017","journal-title":"Cell Death Discov"},{"key":"10.1016\/bs.acr.2026.02.003_bib0060","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3389\/fmicb.2018.02178","article-title":"Adenoviromics: Mining the human adenovirus species D genome","volume":"9","author":"Ismail","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0061","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virusres.2003.12.007","article-title":"Emerging themes in rotavirus cell entry, genome organization, transcription and replication","volume":"101","author":"Jayaram","year":"2004","journal-title":"Virus Res"},{"issue":"23","key":"10.1016\/bs.acr.2026.02.003_bib0062","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1021\/acs.nanolett.3c03516","article-title":"Cell membrane-coated oncolytic adenovirus for targeted treatment of glioblastoma","volume":"23","author":"Jia","year":"2023","journal-title":"Nano Lett"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0063","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41541-023-00706-x","article-title":"The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma","volume":"8","author":"Jiang","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.003_bib0064","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.chembiol.2021.07.005","article-title":"DogCatcher allows loop-friendly protein-protein ligation","volume":"29","author":"Keeble","year":"2022","journal-title":"Cell Chem Biol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0065","first-page":"1","article-title":"The activation of bystander CD8(+) T cells and their roles in viral infection","volume":"51","author":"Kim","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/bs.acr.2026.02.003_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2025.101582","article-title":"Genome-replicating HC-AdV: A novel high-capacity adenoviral vector class featuring enhanced in situ payload expression","volume":"33","author":"Kolibius","year":"2025","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0067","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74660-2","article-title":"Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models","volume":"10","author":"Kunimura","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0068","doi-asserted-by":"crossref","DOI":"10.3390\/v9120356","article-title":"Viral infection and apoptosis","volume":"9","author":"Kvansakul","year":"2017","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.003_bib0069","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: First approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/bs.acr.2026.02.003_bib0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216519","article-title":"Adenoviral gene therapy vectors in clinical use-basic aspects with a special reference to replication-competent adenovirus formation and its impact on clinical safety","volume":"24","author":"Leikas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.acr.2026.02.003_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.743780","article-title":"Autophagy modulation by viral infections influences tumor development","volume":"11","author":"Leonardi","year":"2021","journal-title":"Front Oncol"},{"issue":"19","key":"10.1016\/bs.acr.2026.02.003_bib0072","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.1007\/s00253-016-7806-z","article-title":"Application of conditionally replicating adenoviruses in tumor early diagnosis technology, gene-radiation therapy and chemotherapy","volume":"100","author":"Li","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0073","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2007.135","article-title":"A protocol for rapid generation of recombinant adenoviruses using the AdEasy system","volume":"2","author":"Luo","year":"2007","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0074","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/bs.acr.2026.02.003_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0076","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.molmed.2022.10.001","article-title":"Adenoviruses in medicine: Innocuous pathogen, predator, or partner","volume":"29","author":"MacNeil","year":"2023","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0077","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41598-019-57240-x","article-title":"Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy","volume":"10","author":"Mahasa","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0078","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","article-title":"The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12","volume":"36","author":"Maizel","year":"1968","journal-title":"Virology"},{"issue":"41","key":"10.1016\/bs.acr.2026.02.003_bib0079","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1089\/dna.2022.0115","article-title":"Induction of immune-stimulating factors and oncolysis upon p14(ARF) gene transfer in melanoma cell lines","volume":"42","author":"Mendonca","year":"2023","journal-title":"DNA Cell Biol"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.003_bib0081","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/sj.gt.3301453","article-title":"A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob","volume":"8","author":"Mizuguchi","year":"2001","journal-title":"Gene Ther"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009741","article-title":"Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity","volume":"12","author":"Morita","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.003_bib0083","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/vaccines13040406","article-title":"Next-generation adenoviral vector-based vaccines for severe acute respiratory syndrome coronavirus-2","volume":"13","author":"Murala","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0084","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1189\/jlb.0313153","article-title":"Cellular stress response and innate immune signaling: Integrating pathways in host defense and inflammation","volume":"94","author":"Muralidharan","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"22","key":"10.1016\/bs.acr.2026.02.003_bib0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212461","article-title":"Strategies for modifying adenoviral vectors for gene therapy","volume":"25","author":"Muravyeva","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0086","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/sj.cgt.7700981","article-title":"Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting","volume":"13","author":"Ni","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.003_bib0087","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S2213-2600(24)00368-0","article-title":"PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: A pivotal phase 1\/2 clinical trial","volume":"13","author":"Norberg","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0088","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcb.20523","article-title":"Control of adenovirus packaging","volume":"96","author":"Ostapchuk","year":"2005","journal-title":"J Cell Biochem"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101279","article-title":"Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity","volume":"32","author":"Ozcan","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.003_bib0090","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/mt.2009.80","article-title":"A phase I\/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]","volume":"17","author":"Patel","year":"2009","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0091","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ab.2006.04.032","article-title":"A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers","volume":"354","author":"Peng","year":"2006","journal-title":"Analytical Biochemistry"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.003_bib0092","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1021\/acs.nanolett.2c00931","article-title":"Adenoviral vector for enhanced prostate cancer specific transferrin conjugated drug targeted therapy","volume":"22","author":"Peng","year":"2022","journal-title":"Nano Lett"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0094","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.20892\/j.issn.2095-3941.2024.0390","article-title":"Improving systemic delivery of oncolytic virus by cellular carriers","volume":"21","author":"Peng","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"22","key":"10.1016\/bs.acr.2026.02.003_bib0093","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.3390\/molecules29225315","article-title":"Advancements in p53-based anti-tumor gene therapy research","volume":"29","author":"Peng","year":"2024","journal-title":"Molecules"},{"issue":"24","key":"10.1016\/bs.acr.2026.02.003_bib0095","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1002\/1873-3468.13690","article-title":"Imaging the adenovirus infection cycle","volume":"593","author":"Pied","year":"2019","journal-title":"FEBS Lett"},{"key":"10.1016\/bs.acr.2026.02.003_bib0096","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-319-67577-0_5","article-title":"Immunogenic and non-immunogenic cell death in the tumor microenvironment","volume":"1036","author":"Pitt","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.003_bib0097","article-title":"Twenty years of Gendicine(R) rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology","volume":"11","author":"Qi","year":"2024","journal-title":"Genes Dis"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.003_bib0098","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/1566523220666200826100245","article-title":"Recombinant human p53 adenovirus injection (rAd-p53) combined with chemotherapy for 4 cases of high-grade serous ovarian cancer","volume":"20","author":"Qu","year":"2020","journal-title":"Curr Gene Ther"},{"issue":"1\u20132","key":"10.1016\/bs.acr.2026.02.003_bib0099","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"13","key":"10.1016\/bs.acr.2026.02.003_bib0100","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.3390\/ijms23137023","article-title":"Revisiting regulated cell death responses in viral infections","volume":"23","author":"Rex","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0101","doi-asserted-by":"crossref","first-page":"30015","DOI":"10.3390\/ijms161226215","article-title":"Mesenchymal stem cell-mediated effects of tumor support or suppression","volume":"16","author":"Rhee","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.003_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101497","article-title":"In-vivo-targeted gene delivery using adenovirus-antibody site-specific covalent conjugates","volume":"33","author":"Rice-Boucher","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"28","key":"10.1016\/bs.acr.2026.02.003_bib0103","doi-asserted-by":"crossref","first-page":"45415","DOI":"10.18632\/oncotarget.17557","article-title":"Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model","volume":"8","author":"Rincon","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0104","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Rivera-Orellana","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/bs.acr.2026.02.003_bib0105","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/srep01812","article-title":"Molecular evolution of human adenoviruses","volume":"3","author":"Robinson","year":"2013","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0106","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"Rowe","year":"1953","journal-title":"Proc Soc Exp Biol Med"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.003_bib0107","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/v16071094","article-title":"Clinical application of adenovirus (AdV): A comprehensive review","volume":"16","author":"Salauddin","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0108","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/v15010204","article-title":"The adenovirus vector platform: Novel insights into rational vector design and lessons learned from the COVID-19 vaccine","volume":"15","author":"Sallard","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0109","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2514356","article-title":"Developing the next-generation of adenoviral vector vaccines","volume":"21","author":"Sampson","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/v16030377","article-title":"Advances of recombinant adenoviral vectors in preclinical and clinical applications","volume":"16","author":"Scarsella","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0111","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0112","first-page":"455","article-title":"The interaction of viruses with the cellular senescence response","volume":"9","author":"Seoane","year":"2020","journal-title":"Biology (Basel)"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0113","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12935-021-01848-5","article-title":"MSCs loaded with oncolytic reovirus: Migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL\/6 mice","volume":"21","author":"Seyed-Khorrami","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"7\u20138","key":"10.1016\/bs.acr.2026.02.003_bib0114","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2022.228","article-title":"Review of safety data for adenovirus 5 as a delivery vector for intratumoral cancer gene therapy","volume":"34","author":"Sheldon","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/bs.acr.2026.02.003_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2024.11.001","article-title":"The interplay between cell death and senescence in cancer","volume":"108","author":"Shimizu","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/bs.acr.2026.02.003_bib0116","first-page":"195","article-title":"Adenovirus","volume":"343","author":"Smith","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0117","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.molcel.2006.11.026","article-title":"Acetylation of the p53 DNA-binding domain regulates apoptosis induction","volume":"24","author":"Sykes","year":"2006","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0118","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: Construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"Biotechniques"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0119","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neo.2017.02.010","article-title":"Mesenchymal stem cells induce epithelial to mesenchymal transition in colon cancer cells through direct cell-to-cell contact","volume":"19","author":"Takigawa","year":"2017","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0120","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/15384047.2016.1235655","article-title":"Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy","volume":"17","author":"Tamura","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"suppl 1","key":"10.1016\/bs.acr.2026.02.003_bib0122","doi-asserted-by":"crossref","first-page":"e476s","DOI":"10.6061\/clinics\/2018\/e476s","article-title":"Improving adenoviral vectors and strategies for prostate cancer gene therapy","volume":"73","author":"Tamura","year":"2018","journal-title":"Clinics"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.003_bib0121","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/hum.2016.139","article-title":"Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector","volume":"28","author":"Tamura","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"1\u20132","key":"10.1016\/bs.acr.2026.02.003_bib0123","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41434-019-0071-x","article-title":"Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth","volume":"27","author":"Tamura","year":"2020","journal-title":"Gene Therapy"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0124","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.molcel.2006.11.021","article-title":"Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis","volume":"24","author":"Tang","year":"2006","journal-title":"Mol Cell"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.003_bib0125","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1348-0421.12753","article-title":"Oncolytic viruses: What to expect from their use in cancer treatment","volume":"64","author":"Terrivel","year":"2020","journal-title":"Microbiol Immunol"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.003_bib0126","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.3390\/cancers13081863","article-title":"Nonreplicating adenoviral vectors: Improving tropism and delivery of cancer gene therapy","volume":"13","author":"Tessarollo","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0127","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","article-title":"Oncolytic virus-based suicide gene therapy for cancer treatment: A perspective of the clinical trials conducted at Henry Ford Health","volume":"8","author":"Thoidingjam","year":"2023","journal-title":"Transl Med Commun"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0128","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/14712590903559822","article-title":"Oncolytic (replication-competent) adenoviruses as anticancer agents","volume":"10","author":"Toth","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0129","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1089\/hum.2006.17.556","article-title":"CD46 represents a target for adenoviral gene therapy of malignant glioma","volume":"17","author":"Ulasov","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/bs.acr.2026.02.003_bib0132","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.1","article-title":"Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein","volume":"2","author":"van Erp","year":"2015","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.003_bib0130","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.003_bib0131","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ni.2795","article-title":"Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation","volume":"15","author":"Vander Lugt","year":"2014","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.003_bib0133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010718","article-title":"Viral-mediated activation and inhibition of programmed cell death","volume":"18","author":"Verburg","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/bs.acr.2026.02.003_bib0134","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/485781","article-title":"Positive and negative regulation of cellular immune responses in physiologic conditions and diseases","author":"Vigano","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.003_bib0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4161\/cbt.2.5.440","article-title":"Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5\/3 chimerism","volume":"2","author":"Volk","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/bs.acr.2026.02.003_bib0138","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.omtm.2023.03.008","article-title":"HDAd6\/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells","volume":"29","author":"Wang","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0137","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/bs.acr.2026.02.003_bib0136","doi-asserted-by":"crossref","first-page":"10567","DOI":"10.1128\/JVI.01308-08","article-title":"In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46","volume":"82","author":"Wang","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/bs.acr.2026.02.003_bib0139","article-title":"Research advances in replication-deficient viral vector vaccines","volume":"12","author":"Wang","year":"2025","journal-title":"Front Vet Sci"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.003_bib0140","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.bbadis.2017.02.023","article-title":"Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis","volume":"1863","author":"Wang","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0141","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: Design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0142","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3390\/v13122502","article-title":"Adenovirus biology, recombinant adenovirus, and adenovirus usage in gene therapy","volume":"13","author":"Watanabe","year":"2021","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.003_bib0143","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","article-title":"Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial","volume":"14","author":"Westphal","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.003_bib0144","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro-oncology"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.003_bib0145","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0146","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: From molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.003_bib0147","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1566523220999200731003206","article-title":"Applications of recombinant adenovirus-p53 gene therapy for cancers in the clinic in China","volume":"20","author":"Xia","year":"2020","journal-title":"Curr Gene Ther"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.003_bib0148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0149","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/bs.acr.2026.02.003_bib0151","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.09.004","article-title":"Construction and application of adenoviral vectors","volume":"34","author":"Zhang","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.003_bib0150","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00262-012-1296-3","article-title":"DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model","volume":"61","author":"Zhang","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0152","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929005","article-title":"Double-edged effects of interferons on the regulation of cancer-immunity cycle","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.acr.2026.02.003_bib0153","article-title":"Oncolytic adenovirus: Prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Microbiol"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.003_bib0154","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/nprot.2010.134","article-title":"An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector","volume":"5","author":"Zhou","year":"2010","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.003_bib0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41420-024-01957-w","article-title":"RIPK3 signaling and its role in regulated cell death and diseases","volume":"10","author":"Zhou","year":"2024","journal-title":"Cell Death Discov"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.003_bib0157","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.003_bib0156","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.003_bib0158","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41419-018-0366-7","article-title":"The distinct roles of mesenchymal stem cells in the initial and progressive stage of hepatocarcinoma","volume":"9","author":"Zong","year":"2018","journal-title":"Cell Death Dis"}],"container-title":["Advances in Cancer Research","Viruses as Therapeutic Agents for Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:56:55Z","timestamp":1780592215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X26000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443432361"],"references-count":158,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2026.02.003","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}